Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)
Latest Information Update: 09 May 2023
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 04 May 2023 Status changed from active, no longer recruiting to completed.
- 04 Jul 2022 Planned End Date changed from 31 Oct 2023 to 21 Apr 2023.
- 04 Jul 2022 Planned primary completion date changed from 31 Oct 2023 to 21 Apr 2023.